Form 4: Immuneering Director Buys 5,000 Shares via 10b5-1 Plan

Immuneering Corp Director Peter Feinberg acquired 5,000 shares of Class A Common Stock at $7.18 per share, increasing his beneficial ownership.

Summary

• Peter Feinberg, a Director at Immuneering Corp (IMRX), reported the acquisition of 5,000 shares of Class A Common Stock.
• The transaction is scheduled to occur on September 29, 2025, at a price of $7.18 per share.
• This purchase is being made pursuant to a pre-arranged Rule 10b5-1 trading plan.
• Following this acquisition, Peter Feinberg's direct beneficial ownership will be 141,766 shares.
• Indirect beneficial ownership includes 392,242 shares as General Partner of PF Associates L.P., 476,615 shares as General Partner of PEF LLC., and 115,441 shares as General Partner of S4K Investments LLC.
• Total beneficial ownership for Peter Feinberg, including direct and indirect holdings, will amount to 1,126,064 shares of Class A Common Stock.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director, even under a pre-arranged plan, indicates confidence in the company's valuation and future performance.

Positives

• Director Peter Feinberg is acquiring 5,000 shares of Class A Common Stock, signaling continued confidence in Immuneering Corp's future prospects.
• The transaction is executed under a Rule 10b5-1 trading plan, indicating a pre-scheduled purchase rather than a reaction to immediate market events, which often suggests a long-term positive outlook.

Industry Context

Insider buying, particularly under a Rule 10b5-1 plan, generally signals management's confidence in the company's long-term prospects, aligning with broader trends of executives investing in their own firms.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive signal, potentially boosting investor confidence in Immuneering Corp's stock.

Key Dates

Recommendation

The director's purchase of shares, even if pre-planned under a 10b5-1, signals strong insider confidence in Immuneering Corp's future prospects and current valuation, making it a favorable indicator for potential investors.

Keywords

Immuneering Corp, IMRX, Peter Feinberg, Insider Trading, Stock Purchase, Director, SEC Form 4, 10b5-1 Plan